Revance Therapeutics to Participate in the 27th Annual Piper Jaffray Healthcare Conference
Revance management is scheduled for a fireside chat on
About
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates RT001 topical and RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. The company holds
worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on
"
CONTACT: Investors:
Revance Therapeutics Jeanie Herbert
(714) 325-3584
jherbert@revance.com
Westwicke Partners Leigh Salvo
(415) 513-1281
leigh.salvo@westwicke.com
Trade Media:
Nadine Tosk
(847) 920-9858
nadinepr@gmail.com
Source: News Provided by Acquire Media
